FBR & Co’s Array Biopharma Inc ARRY Stock Holding History

FBR & Co’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-113,500	Closed	-$706K	–	51
2013 Q3	$706K	Buy	+113,500	New	+$674K	1.07%	21

Other funds holding ARRY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FBR & Co's ARRY Position: Q4 2013 in Review

FBR & Co sold out of Array Biopharma Inc (ARRY) in Q4 2013, closing a stake of 113,500 shares — an estimated $706K sold.

FBR & Co first reported a position in ARRY in Q3 2013 and held it in 1 quarter. The position peaked at $706K in Q3 2013. 143 funds tracked by Wall St. Rank hold ARRY as of Q4 2013.

FBR & Co reported no remaining Array Biopharma Inc position as of Q4 2013 after selling out during the quarter.
FBR & Co sold 113,500 Array Biopharma Inc shares in Q4 2013, an estimated $706K.
FBR & Co first reported a position in Array Biopharma Inc in Q3 2013 and held it in 1 quarter.
FBR & Co's Array Biopharma Inc position peaked at $706K in Q3 2013.
143 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q4 2013.

Based on FBR & Co's 13F filing for Q4 2013, filed 11 Feb 2014.